Bayer, J&J’s Xarelto Prevented Repeat Strokes in Analysis
Bayer AG (BAYN) and Johnson & Johnson (JNJ)’s blood-thinner Xarelto was effective in preventing repeat strokes in an analysis of high-risk patients from the Rocket-AF trial, Bayer said today in a study presented at the European Stroke Conference in Hamburg, Germany.
Patients who took Xarelto, known chemically as rivaroxaban, showed a 13 percent lower risk of having another stroke than patients who took the previous standard therapy warfarin, with a similar risk of bleeding as a side effect and lower rates of fatal bleeding, the Leverkusen, Germany-based company said in a statement.
To contact the reporter on this story: Naomi Kresge in New York at email@example.com
To contact the editor responsible for this story: Phil Serafino at firstname.lastname@example.org
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.